Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices

Journal of Neuropathology and Experimental Neurology

Volumn 55, Issue 10, 1996, Pages 1026-1031

  Ono, Yasuhiro ^a,b   Tamiya, Takashi ^a   Ichikawa, Tomotsugu ^a   Kunishio, Katsuzou ^a   Matsumoto, Kengo ^a   Furuta, Tomohisa ^a   Ohmoto, Takashi ^a   Ueki, Keisuke ^b   Louis, David N ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Astrocytoma; CDKN2; Cell cycle; Ki 67; p16

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; GENE PRODUCT; MONOCLONAL ANTIBODY KI 67;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL CYCLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; PRIORITY JOURNAL;

EID: 0029823960     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199655100-00002     Document Type: Article

References (34)

1. Serrano M, Hannon G J, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7
2. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995;92:6289-93
3. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375:506-10
4. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-6
5. INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818-23
6. Jen J, Harper W, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-58
7. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994;54:6338-39
8. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 1995; 55:984-88
9. Moulton T, Samara G, Chung W, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995;146:613-19
10. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-24
11. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 1995;55: 20-23
12. Ueki K, Ono Y, Henson JW, von Deimling A, Louis DN. CDKN2/ p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53
13. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-36
14. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-56
16. Ueki K, Rubio M-P, Ramesh V, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Molec Genet 1994;3:1841-45
17. Merlo A, Herman JG, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1. Nature Med 1995;1:686-92
18. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-21
19. Reifenberger G, Reifenberger J, Ichimura K, Melzter PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-4303
20. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000
21. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. Berlin: Springer-Verlag, 1993
22. Louis DN, von Deimling A, Seizinger BR. A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 1992;141: 777-82
23. Cairns P, Tokino K, Eby Y, Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994;54:1422-24
24. Ono Y, Ueki K, Joseph JT, Louis DN. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol 1996;91:221-25
25. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-18
26. INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-45
27. Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995;11:2145-49
28. Li Y-J, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R. Frequest loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995;11: 597-600
29. Mao L, Merlo A, Bedi G, et al. A novel p16INK4A transcipt. Cancer Res 1995;55:2995-97
30. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995;55:2988-94
31. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73
32. Gerdes J, Lemke H, Baisch H, Walker HH, Schwab U, Stein H. Cell-cycle analysis of a cell proliferation-associated nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-15
33. Burger PC, Scheithauer BW. Tumors of the central nervous system. Washington, DC: Armed Forces Institute of Pathology, 1994
34. Fujimaki T, Matsutani M, Nakamura O, et al. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults. Cancer 1991;67:1629-34